ERBB2 and breast carcinoma: Moreover, the same research group documented that oral oleocanthal treatment (at a dose of 10 mg/kg/day) for 40 days was effective in preventing breast cancer locoregional recurrence in a nude mouse xenograft model generated through orthotopic inoculation of BT-474 breast cancer cells (which represent the luminal B cancer subtype expressing hormone receptors and HER2) [44].